Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

PLXBullishEarningsShort Term

High materiality8/10

Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results

StockNews.AIAug 12, 6:50 AM EDT1 source

Trading thesisImportance 8/10

Bullish setup over 6–12 months on Elfabrio growth, milestone payments, and PRX-115 data.

AI summary

What happened and why it matters

Protalix reported Q2 2026 results showing improving top-line and profitability, with $19.8m in quarterly selling goods revenue and $53.6m year-to-date revenue, aided by Elfabrio sales and a $25m milestone from Chiesi. Net income for the period was positive and cash was $40.7m, supporting PRX-115 enrollment and the 2026 outlook.

Elfabrio global penetration and a $25m Chiesi milestone underpin revenue acceleration.
Full-year 2026 revenue guidance reaffirmed at $78–$83m, supporting upside risk.
Patent extensions strengthen long-term IP moat for Elfabrio and PRX-115.
Cash runway supports ongoing PRX-115 RELEASE enrollment and pipeline progress.

Sentiment rationale

Profitability year-to-date, robust Elfabrio sales, milestone payments, and cash runway reduce downside and support upside from near-term results and IP/ pipeline milestones.

Key facts

01
Q2 2026 selling goods revenue: $19.8m; six months: $27.2m, up vs 2025.
02
Total 2026 revenue YTD: $53.6m, includes $25m milestone from Chiesi.
03
YTD net income: $22.1m; company profitability achieved year-to-date.
04
Cash, cash equivalents & short-term deposits: $40.7m as of 6/30/2026.
05
Elfabrio patent extension to 2035; PRX-115 patent issued 7/7/2026; 2026 guidance reaffirmed.

Earnings

Earnings. The release provides formal quarterly results, confirms guidance, and highlights pipeline milestones, fitting a classic earnings cycle update with strategic IP and partnership context.